Antifungal Resistance in Cryptococcal Infections

Area of Science:

• Medical Mycology
• Infectious Diseases
• Antimicrobial Resistance

Background:

• Azole antifungal use selects for less susceptible Cryptococcus neoformans and Cryptococcus gattii isolates.
• These fungal infections primarily affect immunocompromised individuals, leading to severe and challenging-to-treat conditions.
• Rising antifungal resistance poses a significant threat, especially in resource-limited settings.

Purpose of the Study:

• To review the epidemiology, virulence, and treatment of Cryptococcus infections.
• To analyze antifungal susceptibility testing methods, resistance mechanisms, and clinical outcomes.
• To explore the influence of environmental and host factors, including PK/PD, on therapeutic success.

Main Methods:

• Comprehensive literature review of Cryptococcus neoformans and Cryptococcus gattii.
• Analysis of studies on antifungal resistance mechanisms (genetic and clinical).
• Evaluation of antifungal susceptibility data, including MICs and epidemiological cutoff values (ECVs/ECOFFs).

Main Results:

• Epidemiologic cutoff values (ECVs/ECOFFs) are currently the most reliable method for detecting antifungal resistance in these species.
• Limited clinical breakpoints exist, with only amphotericin B and Cryptococcus neoformans VNI having established ones.
• Understanding genetic resistance mechanisms and host factors is crucial for predicting treatment outcomes.

Conclusions:

• Antifungal resistance in Cryptococcus species is a growing concern, necessitating improved diagnostic and therapeutic strategies.
• Further research into standardized susceptibility testing and clinical breakpoints is essential.
• Host-related factors significantly impact the clinical management and prognosis of Cryptococcus infections.